This page lists the SEC filings reported by Avoro Capital Advisors LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Adverum Biotechnologies, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | IOVANCE BIOTHERAPEUTICS, INC. | 7,020,000 | 4.4% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Kura Oncology, Inc. | 3,105,000 | 4.5% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Mirati Therapeutics, Inc. | 5,555,555 | 9.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | UNITED THERAPEUTICS Corp | 2,865,000 | 6.3% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | PMV Pharmaceuticals, Inc. | 3,060,000 | 6.7% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | AMICUS THERAPEUTICS, INC. | 26,800,000 | 9.5% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | MARINUS PHARMACEUTICALS, INC. | 3,150,000 | 6.3% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Apellis Pharmaceuticals, Inc. | 10,625,000 | 9.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | IVERIC bio, Inc. | 6,750,000 | 5.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | MADRIGAL PHARMACEUTICALS, INC. | 1,660,000 | 9.7% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Mersana Therapeutics, Inc. | 7,550,000 | 7.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Monte Rosa Therapeutics, Inc. | 4,325,000 | 8.9% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Xenon Pharmaceuticals Inc. | 4,900,000 | 7.8% | EDGAR |
| SC 13G | 2023-02-14 | Avoro Capital Advisors LLC | DICE Therapeutics, Inc. | 2,525,555 | 5.3% | EDGAR |
| SC 13G | 2023-02-14 | Avoro Capital Advisors LLC | Ascendis Pharma A/S | 3,100,000 | 5.4% | EDGAR |
| SC 13G | 2023-02-14 | Avoro Capital Advisors LLC | Krystal Biotech, Inc. | 1,410,000 | 5.5% | EDGAR |
| SC 13G | 2023-02-14 | Avoro Capital Advisors LLC | Kymera Therapeutics, Inc. | 3,850,000 | 7.0% | EDGAR |
| SC 13D/A | 2022-09-26 | Avoro Capital Advisors LLC | Aadi Bioscience, Inc. | 2,849,402 | 11.7% | EDGAR |
| SC 13G/A | 2022-02-11 | Avoro Capital Advisors LLC | Xenon Pharmaceuticals Inc. | 4,985,000 | 9.7% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.